Galectin Therapeutics (NASDAQ:GALT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday. Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th. Check Out Our Latest […]
StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a report published on Tuesday. Separately, HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, April 9th. Get Our Latest Stock Analysis […]
StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a report released on Tuesday morning. Separately, HC Wainwright restated a buy rating and set a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, April 9th. View Our Latest Report on […]
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now owns […]